While the expressions of OAT1 and OAT3 were markedly reduced in the hyperuricaemia group compared to the normal control, and intermediate and high EU treatment resulted in the upregulated expressions of OAT1 and OAT3 compared to the hyperuricaemia group (p < 0.01). The gene discussed is SLC22A8; the disease is hyperuricemia.